MetaCap

Kymera Therapeutics (KYMR) vs Neurocrine Biosciences (NBIX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kymera Therapeutics (KYMR) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 74.6% versus a gain of 6.2%. Over five years, KYMR leads with a +114.4% price change compared with +73.1% for NBIX. Neurocrine Biosciences is the larger company by market cap ($15.24 billion vs $9.84 billion), about 1.5 times the size.

Neurocrine Biosciences converts more of its revenue into profit, with a net margin of 16.7% versus -794.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KYMR+74.61%NBIX+6.16%
+116%+49%-19%
Nov 21, 20251 yearNov 20, 2026
KYMR+87.50%NBIX+75.04%
+124%+16%-92%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KYMR versus NBIX key metrics
MetricKYMRNBIX
Share price$115.31$150.57
Market cap$9.84B$15.24B
1-day change-3.42%-3.84%
YTD return+48.19%+6.16%
1-year return+74.61%+6.16%
5-year return+114.37%+73.11%
P/E ratio (TTM)—22.34
Forward P/E—12.24
EPS (TTM)$-3.64$6.74
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$39.21M$2.86B
Revenue growth (YoY)-16.70%+21.45%
Net income (latest FY)$-311.35M$478.60M
Gross margin0.00%98.18%
Operating margin-891.07%21.64%
Net margin-794.04%16.73%
52-week high$142.92$186.12
52-week low$63.69$122.14
Distance from 52-week high-19.32%-19.10%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+25.94%+38.50%
Average volume852.46K1.34M
Shares outstanding85.37M101.22M
Employees2852,500
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KYMR has outperformed NBIX by 68.4 percentage points over the past year.
  • Neurocrine Biosciences is more profitable, keeping 16.7 cents of every revenue dollar as net income versus -794.0 cents for Kymera Therapeutics.
  • Neurocrine Biosciences grew revenue faster in its latest fiscal year (+21.45% vs -16.70%).

About Kymera Therapeutics

KYMR stock →

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 285 employees

About Neurocrine Biosciences

NBIX stock →

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees

KYMR vs NBIX FAQ

Which is bigger, Kymera Therapeutics or Neurocrine Biosciences?

Neurocrine Biosciences (NBIX) is larger, with a market capitalization of $15.24B compared with $9.84B for Kymera Therapeutics (KYMR).

Which stock has performed better over the past year, KYMR or NBIX?

KYMR returned +74.61% over the past 12 months, compared with +6.16% for NBIX (price return, excluding dividends). Past performance does not predict future results.

Are Kymera Therapeutics and Neurocrine Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons